Selumetinib is a benzimidazole derivative with a 1-methyl-1H-benzimidazole core substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1/MEK2 inhibitor and functions as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, antineoplastic agent, and anticoronaviral agent. It belongs to the classes of benzimidazoles, hydroxamic acid esters, monochlorobenzenes, bromobenzenes, organofluorine compounds, and secondary amino compounds.
